(PLXS) Plexus - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US7291321005
Design, Manufacturing, Supply Chain, Services
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 37.1% |
| Value at Risk 5%th | 54.2% |
| Relative Tail Risk | -11.28% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.03 |
| Alpha | -20.84 |
| CAGR/Max DD | 0.45 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.351 |
| Beta | 1.230 |
| Beta Downside | 1.277 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.92% |
| Mean DD | 13.96% |
| Median DD | 15.68% |
Description: PLXS Plexus November 09, 2025
Plexus Corp (NASDAQ:PLXS) is an electronic manufacturing services (EMS) provider headquartered in Neenah, Wisconsin, founded in 1979. It delivers end-to-end solutions-including design, supply-chain management, new-product introduction, and sustained manufacturing-to customers in aerospace/defense, healthcare/life sciences, industrial/commercial, and communications sectors.
According to its FY2023 earnings release, Plexus generated roughly $2.1 billion in revenue (≈5% YoY growth) and posted an adjusted EBITDA margin of about 7.5%, modestly above the EMS industry median of ~6%. The company’s order backlog was near $2.5 billion, providing a multi-quarter cushion against short-term demand swings.
Key macro drivers include the projected 3% YoY rise in U.S. defense spending (FY2025 FYDP) that underpins the aerospace/defense segment, and the continued outsourcing trend in life-sciences manufacturing driven by regulatory complexity. A potential slowdown in consumer-electronics capex could, however, pressure the industrial/commercial line-up.
For a deeper dive into Plexus valuation metrics and peer comparison, the ValueRay platform offers a granular, data-rich view.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (172.9m TTM) > 0 and > 6% of Revenue (6% = 242.0m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA -5.91pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 21.82% (prev 21.05%; Δ 0.77pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 249.2m > Net Income 172.9m (YES >=105%, WARN >=100%) |
| Net Debt (-131.3m) to EBITDA (258.1m) ratio: -0.51 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.58 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (27.4m) change vs 12m ago -1.22% (target <= -2.0% for YES) |
| Gross Margin 10.08% (prev 9.56%; Δ 0.52pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 128.2% (prev 125.6%; Δ 2.63pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 12.71 (EBITDA TTM 258.1m / Interest Expense TTM 11.6m) >= 6 (WARN >= 3) |
Altman Z'' 5.49
| (A) 0.28 = (Total Current Assets 2.40b - Total Current Liabilities 1.52b) / Total Assets 3.14b |
| (B) 0.64 = Retained Earnings (Balance) 2.00b / Total Assets 3.14b |
| (C) 0.05 = EBIT TTM 147.5m / Avg Total Assets 3.15b |
| (D) 1.20 = Book Value of Equity 2.01b / Total Liabilities 1.68b |
| Total Rating: 5.49 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 64.54
| 1. Piotroski 5.50pt |
| 2. FCF Yield 4.13% |
| 3. FCF Margin 3.82% |
| 4. Debt/Equity 0.12 |
| 5. Debt/Ebitda -0.51 |
| 6. ROIC - WACC (= -0.37)% |
| 7. RoE 12.47% |
| 8. Rev. Trend 30.16% |
| 9. EPS Trend 63.62% |
What is the price of PLXS shares?
As of December 14, 2025, the stock is trading at USD 159.91 with a total of 261,267 shares traded.
Over the past week, the price has changed by +6.34%, over one month by +9.35%, over three months by +15.83% and over the past year by -5.06%.
Over the past week, the price has changed by +6.34%, over one month by +9.35%, over three months by +15.83% and over the past year by -5.06%.
Is PLXS a buy, sell or hold?
Plexus has received a consensus analysts rating of 3.80.
Therefor, it is recommend to hold PLXS.
- Strong Buy: 1
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PLXS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 159 | -0.6% |
| Analysts Target Price | 159 | -0.6% |
| ValueRay Target Price | 176.4 | 10.3% |
PLXS Fundamental Data Overview December 02, 2025
Market Cap USD = 3.86b (3.86b USD * 1.0 USD.USD)
P/E Trailing = 22.8355
P/S = 0.9566
P/B = 2.6313
P/EG = 1.61
Beta = 0.812
Revenue TTM = 4.03b USD
EBIT TTM = 147.5m USD
EBITDA TTM = 258.1m USD
Long Term Debt = 92.0m USD (from longTermDebt, last quarter)
Short Term Debt = 54.0m USD (from shortTermDebt, last quarter)
Debt = 175.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -131.3m USD (from netDebt column, last quarter)
Enterprise Value = 3.73b USD (3.86b + Debt 175.5m - CCE 306.8m)
Interest Coverage Ratio = 12.71 (Ebit TTM 147.5m / Interest Expense TTM 11.6m)
FCF Yield = 4.13% (FCF TTM 154.0m / Enterprise Value 3.73b)
FCF Margin = 3.82% (FCF TTM 154.0m / Revenue TTM 4.03b)
Net Margin = 4.29% (Net Income TTM 172.9m / Revenue TTM 4.03b)
Gross Margin = 10.08% ((Revenue TTM 4.03b - Cost of Revenue TTM 3.63b) / Revenue TTM)
Gross Margin QoQ = 9.90% (prev 10.14%)
Tobins Q-Ratio = 1.19 (Enterprise Value 3.73b / Total Assets 3.14b)
Interest Expense / Debt = 1.38% (Interest Expense 2.41m / Debt 175.5m)
Taxrate = -3.55% (negative due to tax credits) (-1.76m / 49.7m)
NOPAT = 152.8m (EBIT 147.5m * (1 - -3.55%)) [negative tax rate / tax credits]
Current Ratio = 1.58 (Total Current Assets 2.40b / Total Current Liabilities 1.52b)
Debt / Equity = 0.12 (Debt 175.5m / totalStockholderEquity, last quarter 1.45b)
Debt / EBITDA = -0.51 (Net Debt -131.3m / EBITDA 258.1m)
Debt / FCF = -0.85 (Net Debt -131.3m / FCF TTM 154.0m)
Total Stockholder Equity = 1.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.51% (Net Income 172.9m / Total Assets 3.14b)
RoE = 12.47% (Net Income TTM 172.9m / Total Stockholder Equity 1.39b)
RoCE = 9.98% (EBIT 147.5m / Capital Employed (Equity 1.39b + L.T.Debt 92.0m))
RoIC = 9.79% (NOPAT 152.8m / Invested Capital 1.56b)
WACC = 10.15% (E(3.86b)/V(4.03b) * Re(10.55%) + D(175.5m)/V(4.03b) * Rd(1.38%) * (1-Tc(-0.04)))
Discount Rate = 10.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.02%
[DCF Debug] Terminal Value 64.71% ; FCFE base≈228.9m ; Y1≈180.8m ; Y5≈119.6m
Fair Price DCF = 57.04 (DCF Value 1.53b / Shares Outstanding 26.8m; 5y FCF grow -25.11% → 3.0% )
EPS Correlation: 63.62 | EPS CAGR: 26.74% | SUE: 2.52 | # QB: 5
Revenue Correlation: 30.16 | Revenue CAGR: 7.13% | SUE: 0.67 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.76 | Chg30d=-0.022 | Revisions Net=-1 | Analysts=6
EPS current Year (2026-09-30): EPS=7.37 | Chg30d=-0.218 | Revisions Net=-4 | Growth EPS=-0.8% | Growth Revenue=+8.6%
EPS next Year (2027-09-30): EPS=8.20 | Chg30d=+0.045 | Revisions Net=+0 | Growth EPS=+11.2% | Growth Revenue=+6.7%
P/E Trailing = 22.8355
P/S = 0.9566
P/B = 2.6313
P/EG = 1.61
Beta = 0.812
Revenue TTM = 4.03b USD
EBIT TTM = 147.5m USD
EBITDA TTM = 258.1m USD
Long Term Debt = 92.0m USD (from longTermDebt, last quarter)
Short Term Debt = 54.0m USD (from shortTermDebt, last quarter)
Debt = 175.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -131.3m USD (from netDebt column, last quarter)
Enterprise Value = 3.73b USD (3.86b + Debt 175.5m - CCE 306.8m)
Interest Coverage Ratio = 12.71 (Ebit TTM 147.5m / Interest Expense TTM 11.6m)
FCF Yield = 4.13% (FCF TTM 154.0m / Enterprise Value 3.73b)
FCF Margin = 3.82% (FCF TTM 154.0m / Revenue TTM 4.03b)
Net Margin = 4.29% (Net Income TTM 172.9m / Revenue TTM 4.03b)
Gross Margin = 10.08% ((Revenue TTM 4.03b - Cost of Revenue TTM 3.63b) / Revenue TTM)
Gross Margin QoQ = 9.90% (prev 10.14%)
Tobins Q-Ratio = 1.19 (Enterprise Value 3.73b / Total Assets 3.14b)
Interest Expense / Debt = 1.38% (Interest Expense 2.41m / Debt 175.5m)
Taxrate = -3.55% (negative due to tax credits) (-1.76m / 49.7m)
NOPAT = 152.8m (EBIT 147.5m * (1 - -3.55%)) [negative tax rate / tax credits]
Current Ratio = 1.58 (Total Current Assets 2.40b / Total Current Liabilities 1.52b)
Debt / Equity = 0.12 (Debt 175.5m / totalStockholderEquity, last quarter 1.45b)
Debt / EBITDA = -0.51 (Net Debt -131.3m / EBITDA 258.1m)
Debt / FCF = -0.85 (Net Debt -131.3m / FCF TTM 154.0m)
Total Stockholder Equity = 1.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.51% (Net Income 172.9m / Total Assets 3.14b)
RoE = 12.47% (Net Income TTM 172.9m / Total Stockholder Equity 1.39b)
RoCE = 9.98% (EBIT 147.5m / Capital Employed (Equity 1.39b + L.T.Debt 92.0m))
RoIC = 9.79% (NOPAT 152.8m / Invested Capital 1.56b)
WACC = 10.15% (E(3.86b)/V(4.03b) * Re(10.55%) + D(175.5m)/V(4.03b) * Rd(1.38%) * (1-Tc(-0.04)))
Discount Rate = 10.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.02%
[DCF Debug] Terminal Value 64.71% ; FCFE base≈228.9m ; Y1≈180.8m ; Y5≈119.6m
Fair Price DCF = 57.04 (DCF Value 1.53b / Shares Outstanding 26.8m; 5y FCF grow -25.11% → 3.0% )
EPS Correlation: 63.62 | EPS CAGR: 26.74% | SUE: 2.52 | # QB: 5
Revenue Correlation: 30.16 | Revenue CAGR: 7.13% | SUE: 0.67 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.76 | Chg30d=-0.022 | Revisions Net=-1 | Analysts=6
EPS current Year (2026-09-30): EPS=7.37 | Chg30d=-0.218 | Revisions Net=-4 | Growth EPS=-0.8% | Growth Revenue=+8.6%
EPS next Year (2027-09-30): EPS=8.20 | Chg30d=+0.045 | Revisions Net=+0 | Growth EPS=+11.2% | Growth Revenue=+6.7%
Additional Sources for PLXS Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle